Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Long-Term Study to Evaluate the Safety and Efficacy of CDB-2914 in Patients with Uterine Myoma

Next Previous
Trial Profile

Phase III Long-Term Study to Evaluate the Safety and Efficacy of CDB-2914 in Patients with Uterine Myoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ulipristal (Primary)
  • Indications Uterine leiomyoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ASKA Pharmaceutical

Most Recent Events

  • 01 Sep 2021 Status changed from active, no longer recruiting to completed.
  • 01 Sep 2021 Results assessing the efficacy and safety of long-term intermittent administration of 10-mg ulipristal acetate (UPA) for symptomatic uterine fibroids in Japanese women published in the Journal of Obstetrics and Gynaecology Research
  • 05 Dec 2018 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top